Sector
PharmaceuticalsOpen
₹501.65Prev. Close
₹477.8Turnover(Lac.)
₹372.16Day's High
₹501.65Day's Low
₹49152 Week's High
₹501.6552 Week's Low
₹270.25Book Value
₹419.8Face Value
₹10Mkt Cap (₹ Cr.)
670.29P/E
14.53EPS
34.39Divi. Yield
027 Jun 2025
12:00 AM
Board Meeting
Agenda : Audited Result
21 Aug 2024
12:00 AM
AGM
Announcement Date: 21 Aug, 2024
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 13.37 | 13.37 | 13.37 | 26.09 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 495.22 | 464.68 | 436.05 | 374.09 |
Net Worth | 508.59 | 478.05 | 449.42 | 400.18 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 575.18 | 514.62 | 322.35 | 355.07 |
yoy growth (%) | 11.76 | 59.64 | -9.21 | -5.42 |
Raw materials | -375.96 | -336.68 | -176.8 | -205.42 |
As % of sales | 65.36 | 65.42 | 54.84 | 57.85 |
Employee costs | -43.74 | -35.88 | -33.78 | -27.82 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 44.67 | 17.61 | 2.54 | -23.42 |
Depreciation | -32.57 | -34.28 | -31.05 | -32.72 |
Tax paid | 4.31 | 13.21 | -1.96 | -3.16 |
Working capital | 55.88 | -86.12 | 20.69 | -11.18 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 11.76 | 59.64 | -9.21 | -5.42 |
Op profit growth | 46.85 | 8.81 | -1.13 | -7.88 |
EBIT growth | 47.2 | 94.58 | 34.96 | 31.88 |
Net profit growth | -9.73 | -759.69 | -69.05 | 31.32 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 647.89 | 601.45 | 555.51 | 600.18 | 548.12 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 647.89 | 601.45 | 555.51 | 600.18 | 548.12 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 30.87 | 11.58 | 10.32 | 8.31 | 43.07 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,682.6 | 94.39 | 4,03,580.14 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,778.5 | 81.52 | 1,80,068.67 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.91 | 1,19,918.75 | 1,485.4 | 1.08 | 4,254.47 | 397.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,404.9 | 60.94 | 1,15,304.87 | 474 | 0.18 | 2,385 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,696.5 | 59.14 | 1,11,428.51 | 382.46 | 0 | 2,126.59 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Pawan Chaudhary
Joint Managing Director
Manu Chaudhary
Deputy Managing Director
Peeyush Jain
Executive Director
Ashutosh Jain
Company Sec. & Compli. Officer
Neha Kodan
Independent Director
Navdeep Sud
Independent Director
Savita Gupta
Whole-time Director
Akshansh Chaudhary
Independent Director
Nps Monga
Independent Director
Jagdish Chander Sharma
Independent Director
Anil Kumar
S C No 857 Cabin No 10 2nd Flr,
N A C Manimajra,
Chandigarh - 160101
Tel: -
Website: http://www.venusremedies.com
Email: investorgrievance@venusremedies.com; complianceoff
Narang Tower,
44 Community Centre, Naraina Ind Area,
New Delhi-110028
Tel: 91-11-41410592-94
Website: www.linkintime.co.in
Email: delhi@linkintime.co.in
Summary
Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted...
Read More
Reports by Venus Remedies Ltd
What is the Venus Remedies Ltd share price today?
What is the Market Cap of Venus Remedies Ltd?
What is the PE and PB ratio of Venus Remedies Ltd?
What is the 52 Week High and Low of Venus Remedies Ltd?
What is the CAGR of Venus Remedies Ltd?
What is the shareholding pattern of Venus Remedies Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
